• In late June 2026, CBIZ, Inc. (NYSE:CBZ) was rebalanced across several Russell indexes, being added to multiple value-focused benchmarks and removed from various growth-oriented indices.
• This broad shift toward value classifications may influence how quantitative and index-based investors view CBIZ’s profile within the professional services space.
• We’ll now examine how CBIZ’s increased inclusion in value-oriented Russell benchmarks interacts with its existing investment narrative and outlook.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

CBIZ Investment Narrative Recap

To own CBIZ, you need to believe in its middle market, recurring service engine and the earnings potential from integrating Marcum, despite pricing and leverage constraints. The broad shift into Russell value indexes is more about how the market classifies CBIZ than about fundamentals, so it does not materially change the near term catalyst around Marcum integration progress or the key risks around pricing pressure and nonrecurring, market sensitive revenue.

The most relevant recent update alongside the index changes is CBIZ’s reaffirmed 2026 revenue guidance of US$2.8 billion to US$2.9 billion, coming after full year 2025 revenue of about US$2.76 billion. For investors watching how the new value index inclusion might intersect with fundamentals, that guidance anchors expectations around modest top line growth while the company continues to work through Marcum integration costs, leverage and ongoing technology investment.

Yet against this renewed value label, investors should still be aware of how sustained pricing pressure could...

CBIZ's narrative projects $3.0 billion revenue and $216.3 million earnings by 2029. This requires 3.3% yearly revenue growth and about a $62 million earnings increase from $154.3 million today.

Uncover how CBIZ's forecasts yield a $41.00 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue of about US$3.1 billion and earnings of roughly US$222 million by 2029, which is far more upbeat than the baseline view. As CBIZ’s shift into value focused Russell indexes is digested, you may find that these bullish expectations around recurring middle market revenue and margin expansion are revisited, so it is worth comparing how differently people can frame the very same business.

Explore 2 other fair value estimates on CBIZ - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your CBIZ research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free CBIZ research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CBIZ's overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.